Polymeric micelles: Nanocarriers for cancer-targeted drug delivery

AAPS PharmSciTech

Volumn 15, Issue 4, 2014, Pages 862-871

  Zhang, Yifei ^a   Huang, Yixian ^a   Li, Song ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

cancer therapy; drug interactive domain; dual functional carrier; micelles; targeted delivery

Indexed keywords

ALPHA TOCOPHEROL; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; EMBELIN; MACROGOL; MACROGOL FARNESYLTHIOSALICYLATE; NANOCARRIER; PACLITAXEL; POLYMER; SALICYLIC ACID DERIVATIVE; UNCLASSIFIED DRUG; DRUG CARRIER; MICELLE;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER THERAPY; CIRCULATION TIME; CONJUGATE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG INTERACTION; DRUG STRUCTURE; HUMAN; HYDROPHOBICITY; MICELLE; PHYSICAL CAPACITY; POLYMERIZATION; PRIORITY JOURNAL; REVIEW; CHEMISTRY; MEDICINAL CHEMISTRY; NEOPLASMS; PROCEDURES;

ANTINEOPLASTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; MICELLES; NEOPLASMS; POLYMERS;

EID: 84905099953     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-014-0113-z     Document Type: Review

References (132)

1. Nie S, Xing Y, Kim GJ, Simons JW. Nanotechnology applications in cancer. Annu Rev Biomed Eng. 2007;9:257-88. (Pubitemid 350246658)
2. Gao Z, Lukyanov AN, Singhal A, Torchilin VP. Diacyllipidpolymer micelles as nanocarriers for poorly soluble anticancer drugs. Nano Lett. 2002;2(9):979-82.
3. Davis ME, Chen Z, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008;7(9):771-82.
4. Gaucher G, Dufresne MH, Sant VP, Kang N, Maysinger D, Leroux JC. Block copolymer micelles: preparation, characterization and application in drug delivery. J Control Release. 2005;109(1-3):169-88. (Pubitemid 41742123)
5. Sutton D, Nasongkla N, Blanco E, Gao J. Functionalized micellar systems for cancer targeted drug delivery. Pharm Res. 2007;24(6):1029-46. (Pubitemid 46798882)
6. Choucair A, Eisenberg A. Control of amphiphilic block copolymer morphologies using solution conditions. Eur Phys J E Soft Matter. 2003;10(1):37-44.
7. Yu Y, Zhang L, Eisenberg A. Morphogenic effect of solvent on crew-cut aggregates of amphiphilic diblock copolymers. Macromolecules. 1998;31(4):1144-54. (Pubitemid 128585095)
8. Shen H, Zhang L, Eisenberg A. Multiple pH-induced morphological changes in aggregates of polystyrene-block-poly(4-vinylpyridine) in DMF/ H 2 O mixtures. J Am Chem Soc. 1999;121(12):2728-40. (Pubitemid 29165510)
9. Geng Y, Dalhaimer P, Cai S, Tsai R, Tewari M, Minko T, et al. Shape effects of filaments versus spherical particles in flow and drug delivery. Nat Nanotechnol. 2007;2(4):249-55. (Pubitemid 46739812)
10. Benahmed A, Ranger M, Leroux JC. Novel polymeric micelles based on the amphiphilic diblock copolymer poly(N-vinyl-2-pyrrolidone)-block-poly(D, L-lactide). Pharm Res. 2001;18(3):323-8. (Pubitemid 32595820)
11. Chung JE, Yokoyama M, Aoyagi T, Sakurai Y, Okano T. Effect of molecular architecture of hydrophobically modified poly(N-isopropylacrylamide) on the formation of thermoresponsive core-shell micellar drug carriers. J Control Release. 1998;53(1-3):119-30. (Pubitemid 28218695)
12. Kim S, Shi Y, Kim JY, Park K, Cheng JX. Overcoming the barriers in micellar drug delivery: loading efficiency, in vivo stability, and micelle-cell interaction. Expert Opin Drug Deliv. 2010;7(1):49-62.
13. Kim TY, Kim DW, Chung JY, Shin SG, Kim SC, Heo DS, et al. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res. 2004;10(11):3708-16. (Pubitemid 38697604)
14. Lee KS, Chung HC, Im SA, Park YH, Kim CS, Kim SB, et al. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat. 2008;108(2):241-50. (Pubitemid 351311357)
15. Kim DW, Kim SY, Kim HK, Kim SW, Shin SW, Kim JS, et al. Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol. 2007;18(12):2009-14. (Pubitemid 350286241)
16. Hamaguchi T, Kato K, Yasui H, Morizane C, Ikeda M, Ueno H, et al. A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation. Br J Cancer. 2007;97(2):170-6. (Pubitemid 47057476)
17. Danson S, Ferry D, Alakhov V, Margison J, Kerr D, Jowle D, et al . Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Br J Cancer. 2004;90(11):2085-91. (Pubitemid 38869710)
18. Matsumura Y, Hamaguchi T, Ura T, Muro K, Yamada Y, Shimada Y, et al. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br J Cancer. 2004;91(10):1775-81. (Pubitemid 39664964)
19. Trubetskoy VS, Torchilin VP. Use of polyoxyethylene-lipid conjugates as long-circulating carriers for delivery of therapeutic and diagnostic agents. Adv Drug Deliv Rev. 1995;16(2-3):311-20.
20. Lukyanov AN, Torchilin VP. Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs. Adv Drug Deliv Rev. 2004;56(9):1273-89. (Pubitemid 38510474)
21. Musacchio T, Laquintana V, Latrofa A, Trapani G, Torchilin VP. PEG-PE micelles loaded with paclitaxel and surface-modified by a PBR-ligand: synergistic anticancer effect. Mol Pharm. 2009;6(2):468-79.
22. Mu L, Chrastina A, Levchenko T, Torchilin VP. Micelles from poly(ethylene glycol) phosphatidyl ethanolamine conjugates (PEG-PE) as pharmaceutical nanocarriers for poorly soluble drug camptothecin. J Biomed Nanotechnol. 2005;1(2):190-5.
23. Wang J, Mongayt DA, Lukyanov AN, Levchenko TS, Torchilin VP. Preparation and in vitro synergistic anticancer effect of vitamin K3 and 1,8-diazabicyclo[5,4,0]undec-7-ene in poly(ethylene glycol)-diacyllipid micelles. Int J Pharm. 2004;272(1-2):129-35. (Pubitemid 38293018)
24. Lukyanov AN, Gao Z, Mazzola L, Torchilin VP. Polyethylene glycol-diacyllipid micelles demonstrate increased acculumation in subcutaneous tumors in mice. Pharm Res. 2002;19(10):1424-9. (Pubitemid 35266545)
25. Parr MJ, Masin D, Cullis PR, Bally MB. Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol). J Pharmacol Exp Ther. 1997;280(3):1319-27. (Pubitemid 27166729)
26. Weissig V, Whiteman KR, Torchilin VP. Accumulation of protein-loaded long-circulating micelles and liposomes in subcutaneous Lewis lung carcinoma in mice. Pharm Res. 1998;15(10):1552-6. (Pubitemid 28465741)
27. Xiao K, Luo J, Fowler WL, Li Y, Lee JS, Xing L, et al. A self-assembling nanoparticle for paclitaxel delivery in ovarian cancer. Biomaterials. 2009;30(30):6006-16.
28. Xiao K, Luo J, Li Y, Lee JS, Fung G, Lam KS. PEG-oligocholic acid telodendrimer micelles for the targeted delivery of doxorubicin to B-cell lymphoma. J Control Release. 2011;155(2):272-81.
29. Torchilin VP. Micellar nanocarriers: pharmaceutical perspectives. Pharm Res. 2007;24(1):1-16. (Pubitemid 44902565)
30. Liu J, Lee H, Allen C. Formulation of drugs in block copolymer micelles: drug loading and release. Curr Pharm Des. 2006;12(36):4685-701. (Pubitemid 44835137)
31. Latere Dwan'Isa JP, Rouxhet L, Preat V, Brewster ME, Arien A. Prediction of drug solubility in amphiphilic di-block copolymer micelles: the role of polymer-drug compatibility. Pharmazie. 2007;62(7):499-504.
32. Coffman R, Kildsig D. Hydrotropic solubilization - mechanistic studies. Pharm Res. 1996;13(10):1460-3. (Pubitemid 26356946)
33. Bauduin P, Renoncourt A, Kopf A, Touraud D, Kunz W. Unified concept of solubilization in water by hydrotropes and cosolvents. Langmuir. 2005;21(15):6769-75. (Pubitemid 41084464)
34. Kim JY, Kim S, Papp M, Park K, Pinal R. Hydrotropic solubilization of poorly water-soluble drugs. J Pharm Sci. 2010;99(9):3953-65.
35. Cui Y. Parallel stacking of caffeine with riboflavin in aqueous solutions: the potential mechanism for hydrotropic solubilization of riboflavin. Int J Pharm. 2010;397(1-2):36-43.
36. Ooya T, Lee S, Huh K, Park K. Hydrotropic nanocarriers for poorly soluble drugs. In: Mozafari MR, editor. Nanocarrier technologies. Netherlands: Springer; 2006. p. 51-73.
37. Landauer J, McConnell H. A study of molecular complexes formed by aniline and aromatic nitrohydrocarbons. J Am Chem Soc. 1952;74(5):1221-4.
38. Charman W, Lai C, Craik D, Finnin B, Reed B. Self-association of nicotinamide in aqueous-solution: N.M.R. studies of nicotinamide and the mono- and di-methyl-substituted amide analogs. Aust J Chem. 1993;46(3):377-85.
39. Rasool AA, Hussain AA, Dittert LW. Solubility enhancement of some water-insoluble drugs in the presence of nicotinamide and related compounds. J Pharm Sci. 1991;80(4):387-93.
40. Sanghvi R, Evans D, Yalkowsky SH. Stacking complexation by nicotinamide: a useful way of enhancing drug solubility. Int J Pharm. 2007;336(1):35-41. (Pubitemid 46551553)
41. Lee J, Lee SC, Acharya G, Chang CJ, Park K. Hydrotropic solubilization of paclitaxel: analysis of chemical structures for hydrotropic property. Pharm Res. 2003;20(7):1022-30. (Pubitemid 36774273)
42. da Silva RC, Spitzer M, da Silva LHM, Watson L. Investigations on the mechanism of aqueous solubility increase caused by some hydrotropes. Thermochim Acta. 1999;328(1-2):161-7. (Pubitemid 129498069)
43. Huh KM, Lee SC, Cho YW, Lee J, Jeong JH, Park K. Hydrotropic polymer micelle system for delivery of paclitaxel. J Control Release. 2005;101(1-3):59-68. (Pubitemid 39600972)
44. Kim JY, Kim S, Pinal R, Park K. Hydrotropic polymer micelles as versatile vehicles for delivery of poorly water-soluble drugs. J Control Release. 2011;152(1):13-20.
45. Opanasopit P, Yokoyama M, Watanabe M, Kawano K, Maitani Y, Okano T. Block copolymer design for camptothecin incorporation into polymeric micelles for passive tumor targeting. Pharm Res. 2004;21(11):2001-8. (Pubitemid 40941219)
46. Kim SH, Tan JP, Nederberg F, Fukushima K, Colson J, Yang C, et al. Hydrogen bonding-enhanced micelle assemblies for drug delivery. Biomaterials. 2010;31(31):8063-71.
47. Yang C, Attia AB, Tan JP, Ke X, Gao S, Hedrick JL, et al. The role of non-covalent interactions in anticancer drug loading and kinetic stability of polymeric micelles. Biomaterials. 2012;33(10):2971-9.
48. Giacomelli C, Schmidt V, Borsali R. Specific interactions improve the loading capacity of block copolymer micelles in aqueous media. Langmuir. 2007;23(13):6947-55. (Pubitemid 47143212)
49. Yokoyama M, Okano T, Sakurai Y, Suwa S, Kataoka K. Introduction of cisplatin into polymeric micelle. J Control Release. 1996;39(2-3):351-6. (Pubitemid 26195838)
50. Nishiyama N, Kato Y, Sugiyama Y, Kataoka K. Cisplatin-loaded polymer-metal complex micelle with time-modulated decaying property as a novel drug delivery system. Pharm Res. 2001;18(7):1035-41. (Pubitemid 32799952)
51. Carstens MG, de Jong PH, van Nostrum CF, Kemmink J, Verrijk R, de Leede LG, et al. The effect of core composition in biodegradable oligomeric micelles as taxane formulations. Eur J Pharm Biopharm. 2008;68(3):596-606. (Pubitemid 351318214)
52. Gao X, Huang Y, Makhov AM, Epperly M, Lu J, Grab S, et al. Nanoassembly of surfactants with interfacial drug-interactive motifs as tailor-designed drug carriers. Mol Pharm. 2013;10(1):187-98.
53. Zhang P, Lu J, Huang Y, Zhao W, Zhang Y, Zhang X, et al. Design and evaluation of a PEGylated lipopeptide equipped with drug-Interactive motifs as an improved drug carrier. AAPS J. 2014;16(1):114-24.
54. Croy SR, Kwon GS. Polymeric micelles for drug delivery. Curr Pharm Des. 2006;12(36):4669-84. (Pubitemid 44835136)
55. Ringsdorf H. Structure and properties of pharmacologically active polymers. J Polym Sci Pol Sym. 1975;51(1):135-53.
56. Broxterman HJ, Georgopapadakou NH. Anticancer therapeutics: "Addictive" targets, multi-targeted drugs, new drug combinations. Drug Resist Updat. 2005;8(4):183-97. (Pubitemid 41446962)
57. Verschraegen CF, Skubitz K, Daud A, Kudelka AP, Rabinowitz I, Allievi C, et al. A phase I and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2009;63(5):903-10.
58. Langer CJ, O' Byrne KJ, Socinski MA, Mikhailov SM, Lesniewski-Kmak K, Smakal M, et al. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J Thorac Oncol. 2008;3(6):623-30.
59. Shiah JG, Sun Y, Kope èková P, Peterson CM, Straight RC, Kope èek J. Combination chemotherapy and photodynamic therapy of targetable N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin/mesochlorin e6-OV-TL 16 antibody immunoconjugates. J Control Release. 2001;74(1-3):249-53. (Pubitemid 32727628)
60. Mi Y, Liu Y, Feng SS. Formulation of docetaxel by folic acid-conjugated D-alpha-tocopheryl polyethylene glycol succinate 2000 (Vitamin E TPGS(2K)) micelles for targeted and synergistic chemotherapy. Biomaterials. 2011;32(16):4058-66.
61. Dong Y, Feng SS. Poly(d, l-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs. Biomaterials. 2005;26(30):6068-76. (Pubitemid 40805612)
62. Mu L, Feng SS. Vitamin E TPGS used as emulsifier in the solvent evaporation/extraction technique for fabrication of polymeric nanospheres for controlled release of paclitaxel (Taxol). J Control Release. 2002;80(1-3):129-44. (Pubitemid 34273754)
63. Yu L, Bridgers A, Polli J, Vickers A, Long S, Roy A, et al. Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability. Pharm Res. 1999;16(12):1812-7. (Pubitemid 30040695)
64. Muthu MS, Kulkarni SA, Xiong J, Feng SS. Vitamin E TPGS coated liposomes enhanced cellular uptake and cytotoxicity of docetaxel in brain cancer cells. Int J Pharm. 2011;421(2):332-40.
65. Zhang Z, Feng SS. Nanoparticles of poly(lactide)/vitamin E TPGS copolymer for cancer chemotherapy: synthesis, formulation, characterization and in vitro drug release. Biomaterials. 2006;27(2):262-70. (Pubitemid 41278528)
66. Liu Y, Huang L, Liu F. Paclitaxel nanocrystals for overcoming multidrug resistance in cancer. Mol Pharm. 2010;7(3):863-9.
67. Dintaman JM, Silverman JA. Inhibition of P-glycoprotein by D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm Res. 1999;16(10):1550-6. (Pubitemid 29510551)
68. Varma MV, Panchagnula R. Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo. Eur J Pharm Sci. 2005;25(4-5):445-53. (Pubitemid 40853872)
69. Cao N, Feng SS. Doxorubicin conjugated to D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS): conjugation chemistry, characterization, in vitro and in vivo evaluation. Biomaterials. 2008;29(28):3856-65.
70. Xu H, Abe H, Naito M, Fukumori Y, Ichikawa H, Endoh S, et al. Efficient dispersing and shortening of super-growth carbon nanotubes by ultrasonic treatment with ceramic balls and surfactants. Adv Powder. 2010;21(5):551-5.
71. Yan A, Von Dem Bussche A, Kane AB, Hurt RH. Tocopheryl polyethylene glycol succinate as a safe, antioxidant surfactant for processing carbon nanotubes and fullerenes. Carbon. 2007;45(13):2463-70. (Pubitemid 47588210)
72. Chandrasekharan P, Maity D, Yong CX, Chuang KH, Ding J, Feng SS. Vitamin E (D-alpha-tocopheryl-co-poly(ethylene glycol) 1000 succinate) micelles-superparamagnetic iron oxide nanoparticles for enhanced thermotherapy and MRI. Biomaterials. 2011;32(24):5663-72.
73. Zhang Z, Tan S, Feng SS. Vitamin E TPGS as a molecular biomaterial for drug delivery. Biomaterials. 2012;33(19):4889-906.
74. Mu L, Elbayoumi TA, Torchilin VP. Mixed micelles made of poly(ethylene glycol)-phosphatidylethanolamine conjugate and d-α-tocopheryl polyethylene glycol 1000 succinate as pharmaceutical nanocarriers for camptothecin. Int J Pharm. 2005;306(1-2):142-9. (Pubitemid 41643148)
75. Chandran T, Katragadda U, Teng Q, Tan C. Design and evaluation of micellar nanocarriers for 17-allyamino-17-demethoxygeldanamycin (17-AAG). Int J Pharm. 2010;392(1-2):170-7.
76. Gao Y, Li LB, Zhai G. Preparation and characterization of Pluronic/TPGS mixed micelles for solubilization of camptothecin. Colloids Surf B: Biointerfaces. 2008;64(2):194-9.
77. Zhao L, Shi Y, Zou S, Sun M, Lil L, Zhail G. Formulation and in vitro evaluation of quercetin loaded polymeric micelles composed of pluronic P123 and D-a-tocopheryl polyethylene glycol succinate. J Biomed Nanotechnol. 2011;7(3):358-65.
78. Wang J, Wang R, Li LB. Preparation and properties of hydroxycamptothecin- loaded nanoparticles made of amphiphilic copolymer and normal polymer. J Colloid Interface Sci. 2009;336(2):808-13.
79. Wang J, Sun J, Chen Q, Gao Y, Li L, Li H, et al. Star-shape copolymer of lysine-linked di-tocopherol polyethylene glycol 2000 succinate for doxorubicin delivery with reversal of multidrug resistance. Biomaterials. 2012;33(28):6877-88.
80. Lu J, Huang Y, Zhao W, Chen Y, Li J, Gao X, et al. Design and characterization of PEG-derivatized vitamin E as a nanomicellar formulation for delivery of paclitaxel. Mol Pharm. 2013;10(8):2880-90.
81. Nikolovska-Coleska Z, Xu L, Hu Z, Tomita Y, Li P, Roller PP, et al. Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database. J Med Chem. 2004;47(10):2430-40. (Pubitemid 38580082)
82. Bhandari U, Jain N, Pillai KK. Further studies on antioxidant potential and protection of pancreatic beta-cells by Embelia ribes in experimental diabetes. Exp Diabetes Res. 2007;2007:15803.
83. Chitra M, Sukumar E, Suja V, Devi CS. Antitumor, anti-inflammatory and analgesic property of embelin, a plant product. Chemotherapy. 1994;40(2):109-13.
84. Singh D, Singh R, Singh P, Gupta RS. Effects of embelin on lipid peroxidation and free radical scavenging activity against liver damage in rats. Basic Clin Pharmacol Toxicol. 2009;105(4):243-8.
85. Li Y, Li D, Yuan S, Wang Z, Tang F, Nie R, et al. Embelin-induced MCF-7 breast cancer cell apoptosis and blockade of MCF-7 cells in the G2/M phase via the mitochondrial pathway. Oncol Lett. 2013;5(3):1005-9.
86. Dai Y, Qiao L, Chan KW, Yang M, Ye J, Ma J, et al. Peroxisome proliferator-activated receptor-gamma contributes to the inhibitory effects of Embelin on colon carcinogenesis. Cancer Res. 2009;69(11):4776-83.
87. Danquah M, Li F, Duke 3rd CB, Miller DD, Mahato RI. Micellar delivery of bicalutamide and embelin for treating prostate cancer. Pharm Res. 2009;26(9):2081-92.
88. Mori T, Doi R, Kida A, Nagai K, Kami K, Ito D, et al. Effect of the XIAP inhibitor Embelin on TRAIL-induced apoptosis of pancreatic cancer cells. J Surg Res. 2007;142(2):281-6. (Pubitemid 47418828)
89. Tamm I, Kornblau SM, Segall H, Krajewski S, Welsh K, Kitada S, et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res. 2000;6(5):1796-803. (Pubitemid 30305074)
90. Berezovskaya O, Schimmer AD, Glinskii AB, Pinilla C, Hoffman RM, Reed JC, et al. Increased expression of apoptosis inhibitor protein XIAP contributes to anoikis resistance of circulating human prostate cancer metastasis precursor cells. Cancer Res. 2005;65(6):2378-86. (Pubitemid 40490149)
91. Vogler M, Walczak H, Stadel D, Haas TL, Genze F, Jovanovic M, et al. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. Cancer Res. 2009;69(6):2425-34.
92. Ahn KS, Sethi G, Aggarwal BB. Embelin, an inhibitor of X chromosome-linked inhibitor-of-apoptosis protein, blocks nuclear factor-kappaB (NF-kappaB) signaling pathway leading to suppression of NF-kappaB-regulated antiapoptotic and metastatic gene products. Mol Pharmacol. 2007;71(1):209-19. (Pubitemid 46020991)
93. Huang Y, Lu J, Gao X, Li J, Zhao W, Sun M, et al. PEG-derivatized embelin as a dual functional carrier for the delivery of paclitaxel. Bioconjug Chem. 2012;23(7):1443-51.
94. Lu J, Huang Y, Zhao W, Marquez RT, Meng X, Li J, et al. PEG-derivatized embelin as a nanomicellar carrier for delivery of paclitaxel to breast and prostate cancers. Biomaterials. 2013;34(5):1591-600.
95. Weisz B, Giehl K, Gana-Weisz M, Egozi Y, Ben-Baruch G, Marciano D, et al. A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice. Oncogene. 1999;18(16):2579-88. (Pubitemid 29216680)
96. Grewal T, Koese M, Tebar F, Enrich C. Differential regulation of RasGAPs in cancer. Genes Cancer. 2011;2(3):288-97.
97. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res. 1989;49(17):4682-9. (Pubitemid 19213607)
98. Downward J. Targeting RAS, signalling pathways in cancer therapy. Nat Rev Cancer. 2003;3(1):11-22. (Pubitemid 37328883)
99. Halaschek-Wiener J, Wacheck V, Schlagbauer-Wadl H, Wolff K, Kloog Y, Jansen B. A novel Ras antagonist regulates both oncogenic Ras and the tumor suppressor p53 in colon cancer cells. Mol Med. 2000;6(8):693-704.
100. Jansen B, Schlagbauer-Wadl H, Kahr H, Heere-Ress E, Mayer BX, Eichler H, et al. Novel Ras antagonist blocks human melanoma growth. Proc Natl Acad Sci U S A. 1999;96(24):14019-24.
101. Barkan B, Starinsky S, Friedman E, Stein R, Kloog Y. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1. Clin Cancer Res. 2006;12(18):5533-42. (Pubitemid 44497271)
102. Blum R, Kloog Y. Tailoring Ras-pathway-inhibitor combinations for cancer therapy. Drug Resist Updat. 2005;8(6):369-80. (Pubitemid 43358060)
103. Gana-Weisz M, Halaschek-Wiener J, Jansen B, Elad G, Haklai R, Kloog Y. The Ras inhibitor S-trans, trans-farnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance. Clin Cancer Res. 2002;8(2):555-65. (Pubitemid 34193977)
104. Zhang X, Lu J, Huang Y, Zhao W, Chen Y, Li J, et al. PEG- farnesylthiosalicylate conjugate as a nanomicellar carrier for delivery of paclitaxel. Bioconjug Chem. 2013;24(3):464-72.
105. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003;23(1A):363-98. (Pubitemid 36361976)
106. Wilken R, Veena MS, Wang MB, Srivatsan ES. Curcumin: a review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Mol Cancer. 2011;10:12.
107. Shishodia S, Amin HM, Lai R, Aggarwal BB. Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem Pharmacol. 2005;70(5):700-13. (Pubitemid 41058705)
108. Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol. 2006;71(10):1397-421.
109. Sharma RA, Gescher AJ, Steward WP. Curcumin: the story so far. Eur J Cancer. 2005;41(13):1955-68. (Pubitemid 41557681)
110. Holy JM. Curcumin disrupts mitotic spindle structure and induces micronucleation in MCF-7 breast cancer cells. Mutat Res. 2002;518(1):71-84. (Pubitemid 34626847)
111. Jiang MC, Yang-Yen HF, Yen JJ, Lin JK. Curcumin induces apoptosis in immortalized NIH 3T3 and malignant cancer cell lines. Nutr Cancer. 1996;26(1):111-20. (Pubitemid 26268581)
112. 6] sensitizes human prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/ Apo2L-induced apoptosis by suppressing nuclear factor-κB via inhibition of the prosurvival Akt signaling pathway. J Pharmacol Exp Ther. 2007;321(2):616-25.
113. Holy J. Curcumin inhibits cell motility and alters microfilament organization and function in prostate cancer cells. Cell Motil Cytoskeleton. 2004;58(4):253-68. (Pubitemid 38989672)
114. Woo JH, Kim YH, Choi YJ, Kim DG, Lee KS, Bae JH, et al. Molecular mechanisms of curcumin-induced cytotoxicity: induction of apoptosis through generation of reactive oxygen species, down-regulation of Bcl-XL and IAP, the release of cytochrome C and inhibition of Akt. Carcinogenesis. 2003;24(7):1199-208. (Pubitemid 36927060)
115. Yoysungnoen P, Wirachwong P, Bhattarakosol P, Niimi H, Patumraj S. Effects of curcumin on tumor angiogenesis and biomarkers, COX-2 and VEGF, in hepatocellular carcinoma cell-implanted nude mice. Clin Hemorheol Microcirc. 2006;34(1-2):109-15. (Pubitemid 43351018)
116. Anuchapreeda S, Limtrakul P, Thanarattanakorn P, Sittipreechacharn S, Chanarat P. Inhibitory effect of curcumin on WT1 gene expression in patient leukemic cells. Arch Pharm Res. 2006;29(1):80-7. (Pubitemid 43268428)
117. Odot J, Albert P, Carlier A, Tarpin M, Devy J, Madoulet C. In vitro and in vivo anti-tumoral effect of curcumin against melanoma cells. Int J Cancer. 2004;111(3):381-7. (Pubitemid 38998818)
118. Yallapu MM, Jaggi M, Chauhan SC. beta-Cyclodextrincurcumin self-assembly enhances curcumin delivery in prostate cancer cells. Colloids Surf B: Biointerfaces. 2010;79(1):113-25.
119. Anand P, Nair HB, Sung B, Kunnumakkara AB, Yadav VR, Tekmal RR, et al. Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem Pharmacol. 2010;79(3):330-8.
120. Shahani K, Panyam J. Highly loaded, sustained-release microparticles of curcumin for chemoprevention. J Pharm Sci. 2011;100(7):2599-609.
121. Zhang F, Koh GY, Jeansonne DP, Hollingsworth J, Russo PS, Vicente G, et al. A novel solubility-enhanced curcumin formulation showing stability and maintenance of anticancer activity. J Pharm Sci. 2011;100(7):2778-89.
122. Safavy A, Raisch KP, Mantena S, Sanford LL, Sham SW, Krishna NR, et al. Design and development of water-soluble curcumin conjugates as potential anticancer agents. J Med Chem. 2007;50(24):6284-8.
123. Tang H, Murphy CJ, Zhang B, Shen Y, Sui M, Van Kirk EA, et al. Amphiphilic curcumin conjugate-forming nanoparticles as anticancer prodrug and drug carriers: in vitro and in vivo effects. Nanomedicine (Lond). 2010;5(6):855-65.
124. Manju S, Sreenivasan K. Conjugation of curcumin onto hyaluronic acid enhances its aqueous solubility and stability. J Colloid Interface Sci. 2011;359(1):318-25.
125. Manju S, Sreenivasan K. Synthesis and characterization of a cytotoxic cationic polyvinylpyrrolidone-curcumin conjugate. J Pharm Sci. 2011;100(2):504-11.
126. Yang R, Zhang S, Kong D, Gao X, Zhao Y, Wang Z. Biodegradable polymer-curcumin conjugate micelles enhance the loading and delivery of low-potency curcumin. Pharm Res. 2012;29(12):3512-25.
127. Yokoyama M, Okano T, Sakurai Y, Ekimoto H, Shibazaki C, Kataoka K. Toxicity and antitumor activity against solid tumors of micelle-forming polymeric anticancer drug and its extremely long circulation in blood. Cancer Res. 1991;51(12):3229-36.
128. Yokoyama M, Kwon GS, Okano T, Sakurai Y, Ekimoto H, Okamoto K, et al . composition-dependent in vivo antitumor activity of adriamycin-conjugated polymeric micelle against murine colon adenocarcinoma 26. Drug Deliv. 1993;1(1):11-9.
129. Yokoyama M, Kwon GS, Okano T, Sakurai Y, Seto T, Kataoka K. Preparation of micelle-forming polymer-drug conjugates. Bioconjug Chem. 1992;3(4):295-301.
130. Yokoyama M, Okano T, Sakurai Y, Kataoka K. Improved synthesis of adriamycin-conjugated poly (ethylene oxide)-poly (aspartic acid) block copolymer and formation of unimodal micellar structure with controlled amount of physically entrapped adriamycin. J Control Release. 1994;32(3):269-77.
131. Yokoyama M, Fukushima S, Uehara R, Okamoto K, Kataoka K, Sakurai Y, et al. Characterization of physical entrapment and chemical conjugation of adriamycin in polymeric micelles and their design for in vivo delivery to a solid tumor. J Control Release. 1998;50(1-3):79-92. (Pubitemid 28044103)
132. Yang T, Wang Y, Li Z, Dai W, Yin J, Liang L, et al. Targeted delivery of a combination therapy consisting of combretastatin A4 and low-dose doxorubicin against tumor neovasculature. Nanomedicine. 2012;8(1):81-92.